Use of restaging primary site biopsy to optimize selection of primary therapy in high stage (III/IV) squamous cancer No significant financial relationships to disclose. This is an ASCO Meeting ...
High complete response (CR) rate in patients (pts) with esophageal carcinoma (EC) undergoing neoadjuvant combination of docetaxel and cisplatin (DC) ± cetuximab(DCE) chemoradiation therapy—a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback